Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | GABRP | O00591 | 1/20 | 0.44 |
| ▸ | GABRD | O14764 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isobutane SCHEMBL2578538 | 0.91 | LMNA (0.52) | LMNAL3MBTL1MAPTRAB9APOLB | |
| SCHEMBL7354123 | 0.91 | LMNA (0.47) | LMNAL3MBTL1MAPTRAB9APOLB | |
| SCHEMBL31334651 | 0.87 | CHRM1 (0.45) | LMNAL3MBTL1MAPTRAB9AALDH1A1 | |
| SCHEMBL4797315 | 0.85 | HPGD (0.50) | LMNAL3MBTL1MAPTRAB9APOLB | |
| SCHEMBL2875175 | 0.85 | NOTUM (0.46) | LMNAL3MBTL1MAPTRAB9APOLB | |
| SCHEMBL652433 | 0.85 | NOTUM (0.46) | LMNAL3MBTL1MAPTRAB9APOLB | |
| SCHEMBL2875954 | 0.85 | NOTUM (0.46) | LMNAL3MBTL1MAPTRAB9APOLB | |
| SCHEMBL26444794 | 0.82 | LMNA (0.52) | LMNAL3MBTL1MAPTRAB9APOLB | |
| SCHEMBL15140649 | 0.82 | HPGD (0.39) | LMNAL3MBTL1MAPTRAB9APOLB | |
| SCHEMBL146591 | 0.81 | MAPT (0.37) | LMNAL3MBTL1MAPTRAB9ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113637148-B | Degradable copolyester based on triethylene glycol, preparation and application | 武汉科技大学 | 2022-11-01 | — | — | CN | claimed |
| CN-113637148-A | Degradable copolyester based on triethylene glycol, preparation and application | 武汉科技大学 | 2021-11-12 | — | — | CN | claimed |
| EP-4719605-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | GlaxoSmithKline Intellectual Property (No.4) Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-20260015321-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED (GB) | 2026-01-15 | — | — | US | disclosed |
| WO-2025226510-A1 | LPAR1 INHIBITORS | ABBVIE INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-12441743-B2 | Spiro aromatic ring compound and use thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2025-10-14 | — | — | US | disclosed |
| US-20250282756-A1 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | STEP PHARMA S.A.S. (FR) | 2025-09-11 | — | — | US | disclosed |
| US-12371419-B2 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | STEP PHARMA S.A.S. (FR) | 2025-07-29 | — | — | US | disclosed |
| EP-4577211-A2 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | Wake Forest University Health Sciences (US) | 2025-07-02 | — | — | EP | disclosed |
| CN-119585241-A | AT2R antagonists and uses thereof | 伊莱利利公司 | 2025-03-07 | — | — | CN | disclosed |
| US-20250074875-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2025-03-06 | — | — | US | disclosed |
| EP-0626968-A1 | PIPERIDINYL THIACYCLIC DERIVATIVES | MERRELL PHARMACEUTICALS INC. (US) | 1994-12-07 | — | — | EP | disclosed |
| US-5371093-A | Piperidinyl thiacyclic derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-12-06 | — | — | US | disclosed |
| EP-0623596-A1 | N-acylpyrrolidines or N-acylpiperidines having a guanidinyl- or amidinyl-substituted side chain as thrombin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993016081-A1 | PIPERIDINYL THIACYCLIC DERIVATIVES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-08-19 | — | — | WO | disclosed |
| WO-1992017475-A1 | HETEROCYCLIC-CYCLIC AMINE DERIVATIVES | PFIZER INC. (US) | 1992-10-15 | — | — | WO | disclosed |
| EP-0462980-A4 | PLATINUM PHARMACEUTICAL AGENTS | — | 1992-03-11 | — | — | EP | disclosed |
| EP-0462980-A1 | PLATINUM PHARMACEUTICAL AGENTS | GEORGETOWN UNIVERSITY (US) | 1992-01-02 | — | — | EP | disclosed |
| WO-1990008157-A1 | PLATINUM PHARMACEUTICAL AGENTS | GEORGETOWN UNIVERSITY (US) | 1990-07-26 | — | — | WO | disclosed |
| CN-1030415-A | Saturated heterocycle carboxamide derivatives and its preparation method | YAMANOUCHI PHARMA CO LTD (JP) | 1989-01-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371419-B2 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | CTPS1, CTPS2, TYMS | LMNA 4409/4885L3MBTL1 4242/4885MAPT 3680/4885 |
| US-20250282756-A1 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | CTPS1, CTPS2, TYMS | LMNA 4396/4885L3MBTL1 4238/4885MAPT 3779/4885 |
| US-20260015321-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | WRN, MSH2, MSH6 | LMNA 2284/4885L3MBTL1 3682/4885MAPT 4063/4885 |
| US-12441743-B2 | Spiro aromatic ring compound and use thereof | PTPN1, PTPN11, PTPN5 | LMNA 4721/4885L3MBTL1 4112/4885MAPT 200/4885 |
| US-20250074875-A1 | AT2R ANTAGONISTS AND USES THEREOF | AGTR2, AGTR1, AVPR2 | LMNA 4260/4885L3MBTL1 4548/4885MAPT 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.